logo

Sorry, but the browser version you are currently using is not supported by this website. We recommend that you update or download a more recent version.

NEWS

We innovate

healthcare solutions

by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.

ABOUT US


Voluntis was founded in 2001 by three entrepreneurs who believed that innovative medical solutions built with advanced information technologies would transform patient lives, enhance medical practices and quality of care by improving medical real-life outcomes and thus increase healthcare system efficiency.

Every day, Voluntis teams seek to invent secure, collaborative and patient-centric digital health solutions with a unique combination of web and mobile development excellence, medical and regulatory expertise and certified quality-orientated processes. With more than 600,000 patients managed and more than 50 programs deployed, our track-record speaks for itself.

  • 600.000
    patients managed
  • 50
    programs deployed

At Voluntis, we are all guided by clear and simple values:

  • We are focused on patients: we are committed to change the daily lives of patients by addressing their unmet needs and by empowering them to manage their chronic condition.
  • We are passionate about innovation: we design next-generation solutions that combine digital and medical expertise to solve the daily problems of patients and care givers.
  • We work with respect and integrity: everyday, we take care of the people we touch, our patients, customers, partners and employees.
  • We are driven by excellence: in everything we do, we behave ethically and we strive to attain the highest level of quality. Always working to enhance our processes, Voluntis is certified ISO 9001, ISO 13485 and compliant with ISO 14971 standard. Our design methodologies embed the harmonized IEC 62304 and IEC 62366 standards.
Pierre LEURENT

Pierre LEURENT

Chief Executive Officer, President of the Management Board and Founder

Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is also president of the telemedicine workgroup of Syntec Numérique, member of the healthcare IT workgroup of SNITEM and member of the steering committee of the Health and Life Sciences group of MEDEF. Pierre is a graduate of the Ecole Centrale Paris engineering school.

Romain MARMOT

Romain MARMOT

Chief Operations Officer, Co-Founder and Member of the Management Board

Romain oversees Voluntis Industrial Operations, including R&D activities, Consulting, Infrastructure, Support and Quality & Validation. Romain has more than 12 years’experience in developing web and mobile medical software. Before founding Voluntis, Romain worked on data analytics for the mass market. He holds an MSc from Ecole Centrale Paris.

Dominique LAUBIER

Dominique LAUBIER

Chief Financial Officer

Dominique has more than 25 years of experience in IT and healthcare. Before joining Voluntis, he served as CFO for Xiring and then Ingenico Healthcare. He began his career as financial analyst and then held progressive positions in finance with Motorola Codex, Racal Datacom France, Cabletron Systems. Dominique is a graduate of ESG Business School and holds the French DECF degree in accounting.

Dr Geneviève D'ORSAY

Dr Geneviève D'ORSAY

Chief Medical Officer

Geneviève has more than 20 years of experience in the life sciences industry. Before joining Voluntis, she was Medical Affairs Director, MD&D, Johnson& Johnson, France & BeNeLux. Prior to this position, she worked for Altana Pharma, Chiesi and Bioprojet. She holds a doctorate in medicine and a degree in pharmacology and clinical research from University of Paris VI as well as a degree in pharmacovigilance from University Descartes, Paris.

Olivier BERROUIGUET

Olivier BERROUIGUET

Chief Commercial Officer

Olivier has 20 years of international experience in IT and healthcare. Prior to joining Voluntis, Olivier was Account Executive at Capgemini, head of Sales and Business Development at Sensitive Object, General Manager at Taylor Hobson, Area Manager Europe and USA at Merck. He began his career in sales at GE Sensing France. Olivier is a graduate of Polytech’Lille engineering school and holds a MBA from HEC.

Alexandre CAPET

Alexandre CAPET

Chief Strategy & Marketing Officer and Member of the Management Board

Before joining Voluntis, Alexandre worked 15 years in the pharmaceutical industry. At Sanofi, he notably headed the Group strategic planning and the M&A for France, where he strongly contributed to build the Diabeo partnership with Sanofi, CERITD and Voluntis. Alexandre is a graduate of HEC and Sciences Po Paris. He holds a master degree in health economics from Paris-Dauphine University.

Etienne VIAL

Etienne VIAL

Vice-President Innovation and Co-Founder.

Etienne manages the innovation activities at Voluntis. Etienne has more than 12 years’ experience in building frameworks, deploying m-health solution, developing algorithms and analytic suites as well as interoperable software. He is a graduate of the Ecole Centrale Paris engineering school.

Patrick Alff

Patrick Alff

Vice-President CIS

Patrick heads our Consulting, Infrastructure and Services department building upon his solid international management experience, which is heavily emphasized on the development of enterprise software and cloud services. Former "Head of Technology Strategy" at British Telecom, "Director of Technology" at Infonet in California, VP R&D and Innovation at OpenTrust and IT transition manager with several other companies, Patrick is keen to promote change, innovation and customer satisfaction. He enjoys combining his entrepreneurial spirit with his passion for technology and management.

Damien McKEON

Damien McKEON

Vice-President Quality & Regulatory Affairs

Before joining Voluntis in 2008, Damien worked at Portsmouth Hospitals NHS Trust. He also worked as a Pharmacist for Boots the Chemists in London. He joined AXA Assistance to coordinate QA and audits of the medical information and pharmacovigilance services provided to pharmaceutical customers. Highlights included managing the preparations for MHRA inspections and implementing a validated, cross-program, health software solution. A Pharmacist by training, Damien also holds a Diploma in Computing from Oxford University.

  • Pierre LEURENT

    Chief Executive Officer, President of the Management Board and Founder

    Pierre LEURENT

  • Romain MARMOT

    Chief Operations Officer, Co-Founder and Member of the Management Board

    Romain MARMOT

  • Dominique LAUBIER

    Chief Financial
    Officer

    Dominique LAUBIER

  • Dr Geneviève D'ORSAY

    Chief Medical
    Officer

    Geneviève D'ORSAY, MD

  • Olivier BERROUIGUET

    Chief
    Commercial
    Officer

    Olivier BERROUIGUET

  • Alexandre CAPET

    Chief Strategy & Marketing Officer and Member of the Management Board

    Alexandre CAPET

  • Etienne VIAL

    Vice-President Innovation and Co-Founder.

    Etienne VIAL

  • Patrick Alff

    Vice-President CIS

    Patrick Alff

  • Damien McKEON

    Vice-President Quality & Regulatory Affairs

    Damien McKEON

Bpifrance

Formed by the law of 31 December 2012, Bpifrance (a public sector investment bank) is the outcome of the merger between OSEO, the FSI, CDC Entreprises and FSI Régions. Its two shareholders are the French state and the Caisse des Dépôts bank. Its object is to support businesses (SMEs, medium-sized enterprises and larger companies of a strategic importance to the French economy), from start-up through to stock market flotation, by providing loans, guarantees and equity. Bpifrance also provides enhanced support and backing for innovation, export, and external growth. With its 42 regional offices, it is a one-stop shop for entrepreneurs in each region for all their finance and investment needs. www.bpifrance.fr - Follow us on Twitter: @bpifrance

Innovation Capital

Founded in 1996, Innovation Capital is an international venture capital firm based in Paris with a local presence in the Silicon Valley. With over €450 million under management, Innovation Capital current focus is on venture and growth investments in the Innovative Healthcare Services space in Europe. Innovation Capital aims to create value by providing talented entrepreneurs with the resources, experience, and network necessary to turn innovative technologies into great businesses.

Vesalius

Vesalius Biocapital is a pan-european venture capital group investing in early stage innovative biotech companies. Most of our investments consist of therapeutic companies, developing new drugs and devices. Our total fund size is €160 million. The team is composed of experienced life science experts and business people.

Qualcomm Incorporated

Qualcomm Incorporated is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm’s licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a wholly-owned subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm’s engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT. For more than 25 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.

CM-CIC Capital Innovation

CM-CIC Capital Innovation specializes in venture capital tech investments. In addition to Sudinnova, it supports the development of companies with strong growth potential in dynamic sectors such as information technologies, healthcare, industrial innovation and the environment. CM-CIC Capital Innovation is a subsidiary of CM-CIC Capital Finance, the investment wing and merchant bank of the Crédit Mutuel-CIC Group. With €2.6 billion in capital (including €1.9 billion in equity), a portfolio of 630 companies, and 6 regional branches throughout France (Paris, Lyon, Nantes, Lille, Strasbourg and Bordeaux), CM-CIC Capital Finance is one of the few merchant banks that invests its own funds for the long term.

CapDecisif Management

CapDecisif Management manages CapDecisif, FCPR CapDecisif 3 and G1J Ile-De-France, early-stage venture capital funds sponsored by Bpifrance, the Ile-de-France region and BNP. Since 2002, the management team has invested in 32 new information technology companies in software, the life sciences, biotech, energy and the environment, and the engineering sciences. CapDecisif Management currently manages almost €100 million.

Sham

Created in 1927, Sham is a mutual insurance company specializing in risk management for healthcare, social and medico-social stakeholders. It is the leading insurer for medical legal liability in France, with an asset portfolio of €1.6 billion invested in various channels. Since 2007, the company has also been investing in innovative healthcare businesses.

Nicolas Cartier

Vice-President of the Board and Member of the Remuneration Committee

Nicolas Cartier is Corporate Vice President, Industrial Microbiology Unit of bioMérieux and member of bioMérieux’s Executive Committee. Before joining bioMérieux, Nicolas was General Manager of Sanofi France from 2009 to 2013. Prior to that, he held various internal positions within Sanofi, in particular in Thailand, where he was in charge of commercial development for the Southeast Asia region within the Animal Health Division, in Shanghai, where he headed up Sanofi China’s Pharmaceutical Division and in Mexico City, where he was General Manager of Sanofi Mexico. In addition, Nicolas was Chief of Staff of the Chairman and CEO of Sanofi. Nicolas is a graduate of Ecole Polytechnique, Ecole des Ponts and Institut d’Etudes Politiques de Paris.

Emilie Lidome

Board Member and Member of Remuneration Committee

Emilie Lidome has a Biological Engineering & Management of Enterprise background, and joined the venture capital field in 2008. Investment Director at CM-CIC Capital Innovation, a subsidiary of the Crédit Mutuel - CIC group's investment and merchant bank division, she invests in high technology companies.
Before joining CM-CIC Capital Innovation, she worked in biotechnology & pharmaceutical industries. She led fundamental research projects and has carried out missions of departments’ coordination consulting in companies such as Novartis or GSK.
Emilie Lidome has graduated from the Université de Technologie de Compiegne in Biological Engineering, and holds a Master degree in Management of Biotechnology Companies from Grenoble Ecole de Management.

Litzie Maarek

Board Member and Member of the Audit Committee

Litzie Maarek is an Investment Director of Bpifrance Large Venture, a €500m fund created in july 2013 in order to finance innovative companies still at venture capital stage and needing large fundraisings. She currently manages and serves as a board member for Large Venture investments in Withings, Voluntis and VI Technology. Prior to that, she was part of Strategic Investment Fund (which was integrated in Bpifrance) and board member of Carso. Litzie Maarek began her career as a Manager in the Leverage Finance team of Crédit Agricole CIB, focusing on mid and large cap operations. Litzie is a graduate of Ecole Centrale Paris.

Alain Parthoens

Board Member

Alain Parthoens is co-founder and managing partner of Vesalius Biocapital funds I & II. He launched his first pan-European life science venture capital fund end of 2007 (VBC I, EUR 76m raised) invested in eleven life science companies. In 2011, Vesalius has raised its second fund (VBC II), reaching EUR 78m , six investments made up to now. Alain Parthoens has 12 years’ experience as venture capitalist not only with Vesalius Biocapital but also with ING Bank where he was the life sciences investment director for South West Europe. Since 2001, he has invested in almost 30 early stage life sciences companies, most of the time in a leading role. As board member he has actively participated in the development of several of them. Additionally, Alain Parthoens has many years of international experience in the food and life sciences businesses including Nestlé, Kemira, Monsanto and consultancy in R&D for pharmaceutical companies with PriceWaterhouseCoopers in London. He was the chairman of the Belgian Venture and Private Equity Association. He is now a member of EVCA VC Council. Alain holds an MSc in agronomy and specialty biochemistry from the Université Catholique de Louvain, an MSc in finance and computer sciences from the Université Libre de Bruxelles and a management degree from the Solvay Business School.

Julie Rachline

Board Member and Member of the Audit Committee

Julie Rachline is an Investment Director at Turenne Capital and represents the interests of SHAM Innovation Sante, managed by Turenne, in Voluntis' Board of Directors. Before joining Turenne Capital, Julie worked as an executive search Principal for two years at L3SPartnership, placing CEOs and C-X- Os within start ups, SMEs and global companies in France and Europe within Healthcare. She previously has gained investment experience first at Atlas Ventures and, then during more than 6 years, at Matignon Investissement et Gestion . Notably, she was actively involved with Nanobiotix, Kadrige or Eurogentec. Julie holds a PhD in Neuropharmacology from Ecole Normale Superieure as well as a Master's degree in marketing from ESCP Europe. During her postgraduate training in science, Julie had worked in France (Institut Pasteur) and in the USA, notably with Roderick MacKinnon (Nobel Prize for Chemistry in 2003 - Rockefeller University) and with Spyros Artavanis-Tsakonas (Yale University ; now Biogen Chief Scientific Officer).

Florian Reinaud

Board Member and Member of Remuneration Committee

Florian Reinaud serves as General Partner at Innovation Capital. Before joining Innovation Capital, Florian was the CFO of DBV Technologies. Prior to that, he worked at Apax Partners and was an equity analyst at Schroder Salomon Smith Barney (Citigroup) covering the pan-European medtech and healthcare services sectors. He also worked as a doctor in the UK’s National Health Service (Accident & Emergency and Internal Medicine). He serves as a member of the Board of FAB Pharma SAS (France), Kuros Biosurgery AG (Switzerland), Zealand Pharma (Denmark) and Orthopaedic Synergy Inc. (USA). Florian holds a medical degree from Imperial College London and a BA (Hons) in Physiology from Oxford University.

Miles Kirby

Observer

Miles Kirby is Managing Director of Qualcomm Ventures, responsible for activities in the European regions. He currently manages and actively serves as a board member or observer for Qualcomm Ventures investments in Anteryon, CallSign, Formula E, Fon, ip.access and Voluntis. Miles has 20 years of experience in the telecommunications industry. Miles previously lead the business development and innovation process in Qualcomm’s Corporate Research and Development group where he formed and drove projects in Augmented Realty, Wireless Charging, Zeroth (New processor architecture derived from the model of the human brain), Indoor position location and Multicore processor optimization. He has an MBA from the Graduate School of Management at the University of California, Irvine and a Bachelor’s degree in Electronics and Communications Engineering degree with honours from Bristol University, UK.

Catherine Boule

Observer

Catherine Boule serves as a Partner and Member of the Management Board at CapDecisif Management SAS. She is responsible for CapDecisif Management investments in the healthcare sector. Catherine worked previously at the Curie Institute, Paris, and also for a high-tech incubator. She serves as a non- executive Director of different companies within the portfolio of CapDecisif Management, including Echosens. She holds a M.Sc. in Molecular Biology from Paris University and a Master's degree in the Management of Biotechnologies.

OUR VISION

We firmly believe that the unprecedented advancement of information
technologies will contribute to solving certain healthcare system issues,
notably related to chronic diseases expansion.


  • QUANTIFIED SELF
  • Personalized
    medicine
  • remote medical
    pratice
  • collaborative
    interactions
  • innovative
    payer model
  • digital
    distribution chanel
  • integrated care
    delivery
  • patients
    empowerment
  • smartphone
    and tablet
    proliferation
  • data driven
    medicine
  • BIG
    DATA

Major mega-trends suggest that the digital healthcare
revolution is already bounding forward in leaps


At Voluntis, we believe these remarkable changes are the pivotal factors that are already transforming healthcare systems. We are poised and ready to catapult the best from advanced technologies towards improving healthcare.

Committed to this vision, Voluntis designs companion software to transform healthcare by :

  • designing integrated care services aligning interests of patients, providers and payers
  • driving cost downwards while improving quality
  • entering new collaborative schemes with stakeholders

OUR OFFER


COMPANION SOFTWARE

At Voluntis, we develop state-of-the-art companion software to accompany
and enhance a specific medication or medical device.

We design our companion software in a user-friendly manner with
the objective of augmenting the real-life value of therapeutics by : 

Means, for instance, designing clinical algorithms that supports decision-making, such as a medication dosage.

Means, in particular, liaising securely patients with care givers in order to activate remote operations, such as monitoring, treatment adjustment or coaching.

Means, for instance, promoting data sharing between the doctor and the patient to foster engagement, and also enabling effective task delegation among healthcare professionals to optimize time.


Companion to an existing medication or medical device, companion software aims at monitoring side-effects, guiding symptom management, promoting adherence, recommending dosage or connecting patients with the healthcare team.

Regulatory wise, our companion software might be classified as software medical device according to prevailing regulation. To comply strictly with regulations, Voluntis has developed an extensive regulatory expertise and implemented high quality standards.

As such, companion software have the potential to empower patient, prevent complications and, ultimately, to augment the real-life value of a medication.

We can conduct clinical studies to demonstrate the value and medical benefits of our companion software. In the field diabetes m-health, our companion is one of the most extensively studied solution. In hemophilia, we have designed a companion software currently under clinical evaluation.

Voluntis develops proprietary companion software but also provides partners with development and regulatory capabilities to elaborate their own companion software.

A COMPANION SOFTWARE FOR

Diabeo® / Insulia®1 product information are specific to a particular country.
Please select the country or region in which you are located. By selecting a country or region, you acknowledge that the information displayed is for the residents of the selected country or region.

Diabeo® / Insulia®1 is a standalone software medical device that combines a mobile application for patients and a web application for healthcare professionals.

Diabeo® / Insulia®1 is not approved for use in the U.S.A.

Diabeo® / Insulia®1 is a standalone software medical device that combines a mobile application for patients and a web application for healthcare professionals.

Diabeo® / Insulia®1,
an insulin companion software

Diabeo® / Insulia®1 provides therapeutic and decision-making support for effective diabetes management to:

  • help adult patients titrate basal and bolus insulin,
  • facilitate interactions between the patient and their healthcare professionals,
  • support remote management and the implementation of telemedicine services.

Diabeo® / Insulia®1 suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on doses that are their own2.


Diabeo® / Insulia®1 was conceived as part
of a significant clinical program :

  • 2013
  • 2008
  • 2007

Diabeo® / Insulia®1 : this medical device is a regulated healthcare product that was granted a CE Mark in 2013.

1Diabeo® is a registered trade-mark of Sanofi. Insulia® is a registered trade-mark of Voluntis.
2For further information, product user should refer to the instruction for use.

Diabeo® / Insulia®1 is a standalone software medical device that combines a mobile application for patients and a web application for healthcare professionals.

Diabeo® / Insulia®1,
an insulin companion software

Diabeo® / Insulia®1 provides therapeutic and decision-making support for effective diabetes management to:

  • help adult patients titrate basal and bolus insulin,
  • facilitate interactions between the patient and their healthcare professionals,
  • support remote management and the implementation of telemedicine services.

Diabeo® / Insulia®1 suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on doses that are their own2.


Diabeo® / Insulia®1 was conceived as part
of a significant clinical program :

  • 2013
  • 2008
  • 2007

Diabeo® / Insulia®1 : this medical device is a regulated healthcare product that was granted a CE Mark in 2013.

1Diabeo® is a registered trade-mark of Sanofi. Insulia® is a registered trade-mark of Voluntis.
2For further information, product user should refer to the instruction for use.

In the anticoagulation treatment, the compliance is crucial: the INR must be regularly measured to ensure the appropriate dosage of the vitamin K antagonist treatment.

In collaboration with Roche Diagnostics, Voluntis has developed a software companion to enhance the CoaguChek INR self-testing device.

This CoaguChek Link solution centralizes the INR data measured by patients, connects patients with the independent diagnostic testing facility and enables effective telemonitoring system by healthcare professionals.

Thus, CoaguChek Link simplifies care delivery, ensures compliance and enables doctors and patients stay connected to work together on managing the anticoagulant treatment.

In hemophilia, we work to help patients managing their condition. This innovative solution intends to simplify the remote monitoring of bleeding events as well as inventory medication management. This solution is currently under clinical evaluation.

OUR EXPERTISE



Medpassport
platform

Medpassport is a comprehensive and highly flexible platform that transforms health data into medical intelligence for better care.

Voluntis develops proprietary companion software but also provides partners with development and regulatory capabilities to elaborate their own digital solution based upon its Medpassport core system architecture.


Cloud operated, Medpassport is a modular
web-based and mobile platform able to:

Collect data, managing device interoperability and seamless integration.

Host data, managing security and complying with privacy rules.

Process the communications flows through configurable roles and workflows in order to coordinate the activities of care providers.

Analyze data and retrieve the relevant information, with an analytics suite incorporating clinical algorithms, automated notification or dashboards in order to support medical decision

Automate effective recall of software medical devices.



The cornerstone

Modular platform, Medpassport enables healthcare organizations to operate remote patient monitoring and to support patient assistance program, for instance to promote therapeutic education, follow-up adverse events or prompt compliance.

Medpassport is also the cornerstone of Voluntis companion software. Tailored to design mobile applications, Medpassport is the underlying platform of our solutions dedicated to diabetes, hemophilia or anticoagulation.


A proven reliability

Highly flexible framework, Medpassport has proven its reliability since it has been implemented in 50+ programs covering more than 20 therapeutic areas. Medpassport has been deployed by 6 top 10 pharmaceutical leaders to support patient-centric initiatives. Medpassport has provided support and monitoring to more than 610 000 patients in 12 countries.



software project
delivery expertise

With over 50 e-health and m-health projects deployed, the Voluntis team has developed a unique expertise in developing software medical devices.

We combine flexibility with regulatory compliance : our
quality certified project methodology follows the Agile
Manifesto
, relying on an interactive approach that encourages :

  • interactions
  • task parallelization
  • responsiveness
  • and customer collaboration

with the aim to deliver a state-of-the-art product or solution.

Beyond being your single person of contact, your Voluntis project manager is the warrant for delivering your project in time and within budget, while ensuring that we fully meet your expectations throughout design, development, validation and delivery phases.

In addition to traditional software management activities, your Voluntis project manager ensures that all topics specific to medical device manufacturing (like human factors, product/patient risk management and clinical evaluations) are addressed by our experts.



Quality and
regulatory
expertise

Focused on patient safety and driven by excellence,
Voluntis’ teams have quality at heart.

Since 2008, our Quality Assurance Department has ensured compliance with regulation and standards, trained employees in our quality processes and managed our product regulatory clearance and registration.


CAREERS

Talented ? Passionate about digital ? Willing to help patients ?
Join Voluntis to innovate healthcare and change patients’ lives. As we always look-out for the next-generation software medical device, a job at Voluntis is demanding and exciting. Our pioneer mindset requires both out-of-the-box thinking and excellence. Our work environment is built to foster enthusiasm, collaboration and creativity.


CONTACT US

Voluntis is headquartered in Paris, France,
and has offices in Boston, USA.



Voluntis FRANCE

Tour Ventôse,
2 rue des Bourets
92150 Suresnes
FRANCE 00 331 41 38 39 20

info@voluntis.com

Voluntis USA

One Broadway
Cambridge, MA 02142
USA

info@voluntis.com

CREDITS

WEBSITE CREATION

POSSUM INTERACTIVE

88, bis rue de Buzenval
75020 PARIS
FRANCE
00 331 83 56 66 90

www.possum-interactive.com

PHOTOS CREDITS

iStockphoto © Geber86 - iStockphoto © bevangoldswain
iStockphoto © AleksandarNakic.